About Adaptate
We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.
UNIQUE BIOLOGY
Our antibodies target gamma delta T cells, a unique class of lymphocytes capable of combining the speed of innate immunity with the selectivity of adaptive immune response.
EXQUISITE SELECTIVITY
Our antibodies selectively target only gamma delta T cells thereby offering the opportunity for superior efficacy and safety over and above conventional immunomodulatory therapies such as pan T cell activators.
BROAD POTENTIAL
Gamma delta T cells recognise malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than any one specific antigen.
INVESTORS
Adaptate Biotherapeutics spun-out from GammaDelta Therapeutics in late 2019.
OUR TEAM
We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.

NATALIE MOUNT, PHD
Chief Executive Officer
Natalie is an experienced leader and innovator with a 25 year track record in drug discovery and development roles.

PETER GOODFELLOW, DPHIL
Chair of the Board
Peter was previously the Balfour Professor of Genetics at the University of Cambridge before working for SmithKline Beecham (later GSK) as Head of Research.

PROFESSOR ADRIAN HAYDAY
Chair of Scientific Advisory Board
Professor Adrian Hayday is a scientific founder of Adaptate and also co-founded GammaDelta Therapeutics in 2016.